Alkem Laboratories Ltd.

Pharma · NSE

₹5,585.50

1Y+10.9%

P/E28.0

Fwd P/E29.2

ROE—

Margin+16.6%

D/E17.06

Div Yld+0.9%

Quality Score48/100

Analyst consensus:Neutral· 21 analysts

52-week range

₹4,671 – ₹5,886

From 52w high

-5.1%

RSI (14)

57.2

vs SMA 50 / 200

↑ 50 · ↑ 200

Alkem Laboratories (ALKEM) is a mid-large Indian pharma company trading at ₹5,585.50, with a trailing PE of 28.04 and a 10.9% 1-year price gain. Two material events have emerged in the trailing two weeks: a USFDA inspection resulting in 7 observations at the Daman plant and the resignation of CEO Dr. Vikas Gupta, both of which dominated recent news flow.

Pros

✓5-year revenue CAGR of 10.7% demonstrates consistent top-line expansion, with free cash flow positive in 4 of 5 tracked years, indicating the business has historically converted revenue growth to cash
✓Debt trend is classified as falling; D/E of 17.06 must be read in pharma-sector context where working capital financing is common, and the declining trajectory is a constructive directional signal
✓Price trades above both the 50-DMA (₹5,434.91) and 200-DMA (₹5,443.11), with RSI at 57.2 (neutral zone) and a modest 5.11% drawdown from the 52-week high, indicating no sustained technical deterioration despite recent negative news
✓Nearest support levels cluster at ₹5,541.82 and ₹5,362.77, providing identifiable structural reference points below current price

Cons

✗5-year earnings CAGR of 1.6% versus revenue CAGR of 10.7% signals that profitability growth has been far weaker than top-line growth — a gap that raises questions about cost structure, pricing power, or one-time adjustments in the base period
✗USFDA issued 7 observations at the Daman facility following a 12-day inspection; unresolved regulatory findings can delay or restrict US product approvals and risk import alerts, which would materially affect export revenue
✗CEO Dr. Vikas Gupta resigned as of 2026-04-24; leadership transitions at the top level during an active regulatory inspection introduce simultaneous operational and strategic uncertainty
✗Quality score of 43 out of 100, ranking 3rd of 6 Pharma sector peers, combined with ROE data absent for most tracking years, limits the ability to confirm whether historical profitability meets a consistent threshold

Recent context

·The USFDA inspection at the Daman plant (concluded approximately 2026-05-02) produced 7 formal observations, which were reported by CNBC TV18, Medical Dialogues, and Moneycontrol; the nature of each observation and Alkem's written response to the FDA will determine the risk severity and timeline for resolution
·CEO resignation on 2026-04-24 was accompanied by a 3-5% intraday decline on announcement day; the market response since then has been relatively contained with the stock recovering to above both moving averages, though no successor announcement was visible in recent headlines
·With 7 of 8 recent articles classified as negative and forward PE of 29.20 marginally above trailing PE of 28.04, the current valuation reflects near-flat near-term earnings growth expectations against a backdrop of active regulatory and leadership risk

Questions to ask yourself

?How many of the 7 USFDA observations are classified as major versus minor, and what is Alkem's historical track record for resolving FDA findings at other facilities — and in what timeframes?
?Does the 5-year revenue-to-earnings growth gap (10.7% vs 1.6%) reflect a structural cost problem, a temporary investment cycle, or accounting items, and has management provided guidance on when margin recovery might appear in reported numbers?
?Who is the likely internal or external successor to CEO Dr. Vikas Gupta, and does Alkem have a documented succession plan that reduces key-person risk during the active regulatory review period?
?Given that US exports are a significant revenue channel for most large Indian pharma companies, what proportion of ALKEM's revenue is US-dependent, and how does the Daman plant's share of that output affect the materiality of an import alert scenario?

28.0

Forward PE

29.2

ROE

—

Profit margin

+16.6%

D/E

17.06

Dividend yield

+0.9%

Quality score

43/100

ROE 5y above 15%

3/5 yrs

FCF 5y positive

4/5 yrs

Analyst consensus2.52 · 21 analysts(1–5 scale, lower = more constructive)

Backtest a strategy on ALKEM Walk-forward test ALKEMBrowse all stocks

For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.